Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention

[1]  Sunil V. Rao,et al.  Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. , 2019, International journal of cardiology.

[2]  J. W. Louwerenburg,et al.  High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. , 2018, International journal of cardiology.

[3]  Hong-Guang Xie,et al.  Increased Risk for Developing Major Adverse Cardiovascular Events in Stented Chinese Patients Treated with Dual Antiplatelet Therapy after Concomitant Use of the Proton Pump Inhibitor , 2014, PloS one.

[4]  G. Lip,et al.  Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. , 2013, European heart journal.

[5]  Ronald D Lee,et al.  A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. , 2012, Journal of the American College of Cardiology.

[6]  Y. Huang,et al.  Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. , 2012, Archives of medical research.

[7]  M. Pfisterer,et al.  Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial , 2012, Journal of internal medicine.

[8]  J. Borovička,et al.  Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study , 2012, Wiener Medizinische Wochenschrift.

[9]  A. Gavazzi,et al.  Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation , 2011, Coronary artery disease.

[10]  K. Harjai,et al.  Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention: An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators , 2011, Circulation. Cardiovascular interventions.

[11]  Deepak L. Bhatt,et al.  Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. , 2011, The American journal of cardiology.

[12]  J. Ferrières,et al.  Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry , 2011, Circulation.

[13]  S. Saito,et al.  [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. , 2010, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[14]  Felix W Frueh,et al.  Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study , 2010, Pharmacotherapy.

[15]  G. Montalescot,et al.  Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. , 2010, Journal of the American College of Cardiology.

[16]  K. Olden,et al.  Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention , 2010, Digestive Diseases and Sciences.

[17]  Y. Loke,et al.  Meta‐analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel , 2010, Alimentary pharmacology & therapeutics.

[18]  K. Kent,et al.  Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. , 2010, The American journal of cardiology.

[19]  P. Binkley,et al.  Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor After Stent Placement for Acute Myocardial Infarction , 2010, Clinical cardiology.

[20]  C. Fakiolas,et al.  The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. , 2010, The Canadian journal of cardiology.

[21]  E. Antman,et al.  Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials , 2009, The Lancet.

[22]  Dominique Mottier,et al.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. , 2008, Journal of the American College of Cardiology.

[23]  B. Gersh.  Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) Registry , 2012 .

[24]  S. Sawada,et al.  Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. , 2009, Internal medicine.